Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 0.84 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.60 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.60 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.60 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | VDR | P11473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9322047 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL11052811 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL18583333 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL13015734 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL11056472 | 0.93 | GPBAR1 (0.84) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL11061114 | 0.93 | GPBAR1 (0.84) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL19278643 | 0.92 | GPBAR1 (1.00) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL19278483 | 0.92 | GPBAR1 (1.00) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL23961019 | 0.91 | GPBAR1 (0.72) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL17303267 | 0.90 | GPBAR1 (0.74) | GPBAR1NR1H4MEN1KMT2AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000526-B2 | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size | DR. FALK PHARMA GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-10000526-B2 | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size | DR. FALK PHARMA GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-20170057990-A1 | Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size | DR. FALK PHARMA GMBH (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057990-A1 | Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size | DR. FALK PHARMA GMBH (DE) | 2017-03-02 | — | — | US | disclosed |
| US-9512167-B2 | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size | DR. FALK PHARMA GMBH (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512167-B2 | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size | DR. FALK PHARMA GMBH (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20140050791-A1 | Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size | DR. FALK PHARMA GMBH (DE) | 2014-02-20 | — | — | US | disclosed |
| US-20140050791-A1 | Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size | DR. FALK PHARMA GMBH (DE) | 2014-02-20 | — | — | US | disclosed |
| EP-2468762-A1 | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size | Dr. Falk Pharma Gmbh (DE) | 2012-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057990-A1 | Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size | SLC10A1, ABCB11, NR1H4 | GPBAR1 8/4885NR1H4 3/4885MEN1 3817/4885 |
| US-20140050791-A1 | Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size | SLC10A1, ABCB11, NR1H4 | GPBAR1 8/4885NR1H4 3/4885MEN1 3829/4885 |
| US-10000526-B2 | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size | SLC10A1, ABCB11, NR1H4 | GPBAR1 8/4885NR1H4 3/4885MEN1 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.